Warberg Asset Management LLC Inhibikase Therapeutics, Inc. Transaction History

Warberg Asset Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	BUY	$0.63 - $1.44 $630 - $1,440	1,000 Added 7.41%	14,493 $11,000
Q1 2022 May 13, 2022	BUY	$1.03 - $1.77 $1,028 - $1,768	999 Added 8.0%	13,493 $20,000
Q4 2021 Feb 14, 2022	SELL	$1.38 - $2.17 $18,638 - $29,308	-13,506 Reduced 51.95%	12,494 $18,000
Q3 2021 Nov 15, 2021	SELL	$1.79 - $2.81 $114,560 - $179,840	-64,000 Reduced 71.11%	26,000 $49,000
Q2 2021 Aug 16, 2021	BUY	$2.8 - $6.23 $251,999 - $560,700	90,000 New	90,000 $252,000

1.03M

Ticker IKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,227,100
Market Cap $33.8M
Description
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointes...

Get notified when there are updates to the investment portfolio of Warberg Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Warberg Asset Management LLC with notifications on news.